BOT - Anything but charting, page-4574

Interesting statement this IMO

Other pipeline products
Botanix continues work to finalize the clinical study report for its rosacea study with BTX 1702 and
close out activities at the various clinical sites in Australia and New Zealand, as well as complete the
data package for ethics approval for the BTX 1801 development program, following the
announcement of positive data from the Phase 2a study. The Company’s focus remains, however, on
preparing for and securing the approval of SB given the near term commercial and revenue generating
potential for that product.
In parallel Botanix continues to explore opportunities to add soon to be approved and marketed
products to its pipeline to bolster the revenue generation potential of the Company and to enhance
its attractiveness, as both a stand-alone company or an M&A target.